Read more at Pharmaceutical Technology• April 5, 2023
Category: AbSci
Synthetic biology innovator opens new campus to speed up drug discovery
Read more in BioPharma-Reporter • October 21, 2021
Absci opens door to new biotechnology campus
Read more in GlobeNewswire • October 20, 2021
Absci and EQRx in tie-up to accelerate production of cheaper, protein based therapeutics
Read more in BioPharma • October 6, 2021
EQRx and Absci announce partnership to discover and develop next-generation protein-based drugs
Read more in Yahoo Finance • October 6, 2021
Absci to participate in the BofA Securities 2021 Tech Solutions for drug discovery conference
Read more in Yahoo! Finance • September 13, 2021
AbSci announces acquisition of target discovery company Totient
Read now on prnewswire.com • June 14, 2021
Vancouver-based AbSci wins $125 million from new investors
Read now on columbian.com • March 23, 2021
AbSci announces completion of $125 million crossover financing to advance AI-powered synthetic biology drug creation platform
Read now on prnewswire.com • March 23, 2021
Inslee: State’s investment in Vancouver’s AbSci is money well-spent
Read now on Columbian.com • February 20, 2020
Columbia Ventures Corporation 